Brainreader’s volumetric analysis has the potential to reliably and objectively characterize pathologic change related to many disease processes […] This objective analysis may help establish the initial diagnosis and assist in monitoring treatment response over time.
We are very enthusiastic about the opportunity to test Brainreader’s segmentation software, Neuroreader, for volume quantification of various brain structures shown to be predictive of the development of AD.
Neuroreader has definitely changed my role in the evaluation of patients with neurodegenerative diseases – not in a few days’ time but from the moment the patient leaves the magnet.
We believe that clinical translation of the new Neuroreader technology has the potential to improve the early diagnosis of AD and to optimize therapeutic strategies. We are excited to be one of the first in the United States to offer Neuroreader to the patients we serve.